Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

NCT05245539 is registered in ClinicalTrials.gov with Cerevel Therapeutics, LLC as lead sponsor.

NCT NCT05245539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
Lead sponsor
Cerevel Therapeutics, LLC
Phase
Phase 1
Overall status
Completed
Start date
January 24, 2022
Completion date
November 14, 2022
Enrollment
151 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

blood pressure, schizophrenia